LianBio Announces $310 Million Crossover Financing to Advance Innovative Therapies in Cardiovascular, Renal, and Oncology Areas

SHANGHAI and PRINCETON, N.J. – October 29, 2020 – LianBio, a China-based company focused on bringing transformative medicines to patients in China and key Asian markets, today announced the successful closing of an oversubscribed $310 million crossover financing round, following its founding and initial funding from Perceptive Advisors.

This financing round was co-led by renowned U.S. biopharmaceutical investment firms RA Capital and Venrock Healthcare Capital Partners, together with China’s SDIC Investment Management. Other biopharmaceutical investors participating in this round included funds under BlackRock, Casdin Capital, Farallon, Logos Capital, Perceptive Advisors, Pfizer, Sphera Healthcare, funds under T. Rowe Price Associates, Inc., Tybourne Capital Management, Vida Ventures, Viking Global Investors, and Wellington Management.

“We are delighted to partner with these world-class investors, who share our vision of accelerating the availability of innovative medicines with disruptive potential for patients in China and other major Asian markets. Building on the momentum from LianBio’s recent establishment and successful development, this financing round provides further support, enabling us to continue addressing significant unmet clinical needs in these regions and contributing to the advancement of China’s life sciences sector.”Konstantin Poukalov, Managing Director at Perceptive Advisors and Executive Chairman of LianBiostated, “We are proud of our management team’s exceptional execution capabilities, as they accelerate the realization of our vision and demonstrate that teamwork, coupled with a strong passion for and commitment to clinical R&D, can facilitate the rapid launch of the world’s most innovative medicines in the Chinese pharmaceutical market.”

This round of financing demonstrates that the company’s global innovation expansion platform has gained recognition from top-tier global investors, and LianBio is confident in continuing to advance its business model in China and other major Asian markets.SDIC Capital will also fully leverage its industrial ecosystem resources in China’s pharmaceutical and healthcare sector to support LianBio’s rapid and healthy development in the Chinese market.

Jefferies LLC served as the exclusive financial advisor for this round of financing.

LianBio’s mission is to deliver high-quality, disruptive therapeutics and scientific treatments to patients in China and other key Asian markets through efficient product development, enabled by strategic collaborations with leading global biopharmaceutical companies. By partnering with world-class collaborators across diverse therapeutic areas and geographies, LianBio has built a disease-relevant product pipeline that leverages translational mechanisms and precision therapies to improve patient outcomes. For more information, please visit lianbio.com.

SDIC Merchants is a professional private equity management firm, with its team managing cumulative assets exceeding RMB 100 billion. Its investors include financial institutions, the National Social Security Fund, as well as state-owned and private capital. The management team has long focused on investments in the advanced manufacturing industry, emphasizing the value of technological innovation, outstanding entrepreneurs, and teams. It prioritizes investments in sectors such as intelligent manufacturing, intelligent and new energy vehicles, life sciences, and information and communications technology (ICT), striving to promote the green, digital, and service-oriented development of the manufacturing sector.

Thomas Hoffmann

Solebury Trout

+1 646-378-2931

thoffmann@soleburytrout.com  

Vincent Lian

Easy PR

+86 18616687388

Lv@easy-pr.hk

Hannah Gendel

Solebury Trout

+1 646-378-2943

hgendel@soleburytrout.com